Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 4/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 6/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.36 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.36 |
| ▸ | BCL2L11 | O43521 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30261896 | 1.00 | TAS2R14 (0.40) | TAS2R14CXCR3MCL1DAGLAPSEN1 | |
| SCHEMBL21930197 | 1.00 | TAS2R14 (0.40) | TAS2R14CXCR3MCL1DAGLAPSEN1 | |
| SCHEMBL21930389 | 0.88 | TAS2R14 (0.41) | TAS2R14CXCR3DAGLAPSEN1PSEN2 | |
| SCHEMBL30483467 | 0.87 | ALDH1A1 (0.36) | TAS2R14MCL1BCL2L11LMNA | |
| SCHEMBL21930384 | 0.85 | TAS2R14 (0.40) | TAS2R14CXCR3PSEN1PSEN2APH1B | |
| SCHEMBL25874011 | 0.81 | MCL1 (0.41) | MCL1BCL2L11 | |
| SCHEMBL21993713 | 0.81 | PSEN1 (0.45) | TAS2R14CXCR3PSEN1PSEN2APH1B | |
| SCHEMBL21930443 | 0.80 | MCL1 (0.63) | MCL1BCL2L11 | |
| SCHEMBL21930487 | 0.79 | MCL1 (0.41) | MCL1BCL2L11 | |
| SCHEMBL30261895 | 0.79 | MCL1 (0.41) | MCL1BCL2L11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3877390-A1 | SPIRO-SULFONAMIDE DERIVATIVES AS INHIBITORS OF MYELOID CELL LEUKEMIA-1 (MCL-1) PROTEIN | Prelude Therapeutics, Incorporated (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | PRELUDE THERAPEUTICS, INCORPORATED | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130769-B2 | Spiro-sulfonamide derivatives as inhibitors of myeloid cell leukemia-1 (MCL-1) protein | MCL1, BCL2A1, BCL2L1 | TAS2R14 4194/4885CXCR3 3264/4885MCL1 1/4885 |
| US-20200148705-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | TAS2R14 4194/4885CXCR3 3264/4885MCL1 1/4885 |
| US-20230010358-A1 | Spiro-Sulfonamide Derivatives As Inhibitors Of Myeloid Cell Leukemia-1 (MCL-1) Protein | MCL1, BCL2A1, BCL2L1 | TAS2R14 4194/4885CXCR3 3264/4885MCL1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.